IV ANTIBIOOTTIHOITO

[Bb]

Lähettäjä: Soijuv Lähetetty: 7.8.2005 12:54

Ensimmäistä kertaa tutkimus jossa selvitettiin pitkän IV antibioottihoidon vaikutusta krooniseen neuroborrelioosiin. Tutkimuksen mukaan pitkä IV antibioottihoito auttoi merkittävästi kroonista borrelioosia sairastavia. Potilaille annettiin antibioottia suonensisäisesti 10 viikon ajan. Potilaat olivat saaneet aiemmin 3 viikon IV antibioottihoidon, mutta heidän oireensa olivat palanneet. Alustavaa tietoa tutkimuksesta:


http://www.lymediseaseassociation.org/Fallon_Study.pdf

Jackson, New Jersey, November 2, 2004

Patients with chronic Lyme disease retreated with 10 weeks of intravenous antibiotics showed significant improvement in cognition and other symptoms, said Columbia University neuropsychiatrist Brian Fallon, MD.

To be eligible for the study, patients had to have chronic Lyme disease with ongoingmemory impairment. All had previously been treated with at least 3 weeks of IVantibiotics and relapsed. All patients in the study were tested with cutting-edge brainimaging techniques, and significant improvement in neurocognitive function was seen over the 10-week IV antibiotic retreatment period. "This is the first randomized controlled trial of chronic neurologic Lyme disease; the results support the benefit of a repeated course of longer-term intravenous antibiotic therapy for patients with a return of cognitive problems", said Fallon.

August 6, 2005

Treatment available for chronic Lyme

Dr. Gary Wormser (Letters, July 18 ) presents the tired argument of the Infectious Diseases Society of America that long-term antibiotic therapy is risky and useless in chronic Lyme disease. The International Lyme and Associated Diseases Society disputes that opinion.

ILADS is an international organization of health care providers who treat an estimated 50,000 to 100,000 patients with Lyme and associated tick-borne illnesses. Both organizations have published guidelines for the management of Lyme disease that are listed by the National Guidelines Clearinghouse, but that's where the similarity ends.

Based on obsolete science, the Infectious Diseases Society guidelines ignore patients with chronic Lyme disease. In contrast, our group advocates treating these patients and finds many improve with extended therapy.

In support of this approach, a recently completed Columbia University study funded by the National Institutes of Health demonstrated significant benefit for chronic Lyme disease patients retreated with long-term antibiotics. Preliminary results of this trial are available on the Lyme Disease Association Web site (www.lymediseaseassociation.org), with formal publication expected soon.

ILADS health care providers offer hope to patients with chronic Lyme disease through effective and appropriate treatment.

Dr. Steven Phillips
President, International Lyme and Associated Diseases Society, Bethesda, Md.